Train Babcock Advisors LLC Has $2.25 Million Holdings in Danaher Co. (NYSE:DHR)

Train Babcock Advisors LLC lowered its position in shares of Danaher Co. (NYSE:DHR) by 5.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,256 shares of the conglomerate’s stock after selling 1,390 shares during the quarter. Train Babcock Advisors LLC’s holdings in Danaher were worth $2,252,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Danaher by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 41,488,407 shares of the conglomerate’s stock worth $3,501,206,000 after buying an additional 520,776 shares in the last quarter. BlackRock Inc. grew its holdings in Danaher by 3.2% in the 2nd quarter. BlackRock Inc. now owns 39,201,798 shares of the conglomerate’s stock worth $3,308,239,000 after buying an additional 1,233,876 shares in the last quarter. FMR LLC grew its holdings in Danaher by 0.9% in the 2nd quarter. FMR LLC now owns 19,624,350 shares of the conglomerate’s stock worth $1,656,100,000 after buying an additional 183,183 shares in the last quarter. Parnassus Investments CA grew its holdings in Danaher by 0.3% in the 3rd quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock worth $840,351,000 after buying an additional 29,381 shares in the last quarter. Finally, Flossbach Von Storch AG grew its holdings in Danaher by 17.2% in the 3rd quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock worth $581,324,000 after buying an additional 994,902 shares in the last quarter. Institutional investors and hedge funds own 76.11% of the company’s stock.

Shares of Danaher Co. (DHR) traded up $0.08 during trading hours on Wednesday, hitting $99.47. The stock had a trading volume of 2,227,300 shares, compared to its average volume of 2,488,430. The firm has a market capitalization of $69,320.00, a P/E ratio of 29.60, a P/E/G ratio of 2.15 and a beta of 1.03. Danaher Co. has a 12 month low of $78.97 and a 12 month high of $100.27. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.95 by $0.05. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The company had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. During the same period last year, the business posted $0.87 earnings per share. The firm’s revenue was up 9.6% compared to the same quarter last year. research analysts predict that Danaher Co. will post 3.99 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be given a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend is Thursday, December 28th. Danaher’s dividend payout ratio (DPR) is presently 16.67%.

In other news, Director Donald J. Ehrlich sold 10,578 shares of Danaher stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $90.82, for a total value of $960,693.96. Following the completion of the transaction, the director now owns 104,621 shares in the company, valued at $9,501,679.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Daniel Raskas sold 37,870 shares of Danaher stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 273,810 shares of company stock worth $25,218,813. 12.20% of the stock is owned by company insiders.

A number of equities analysts have issued reports on the company. Goldman Sachs Group reissued a “neutral” rating and set a $83.00 price objective on shares of Danaher in a research note on Tuesday, September 26th. Robert W. Baird restated a “buy” rating on shares of Danaher in a report on Friday, January 12th. Evercore ISI initiated coverage on Danaher in a report on Wednesday, January 3rd. They issued an “outperform” rating for the company. Royal Bank of Canada restated a “hold” rating and issued a $96.00 target price on shares of Danaher in a report on Thursday, January 4th. Finally, Cowen restated a “buy” rating and issued a $90.00 target price on shares of Danaher in a report on Wednesday, October 4th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $94.91.

WARNING: “Train Babcock Advisors LLC Has $2.25 Million Holdings in Danaher Co. (NYSE:DHR)” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://ledgergazette.com/2018/01/17/train-babcock-advisors-llc-has-2-25-million-holdings-in-danaher-co-dhr.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply